A three-year trial of atromid therapy in exudative diabetic retinopathy.

作者信息

Duncan L J, Cullen J F, Ireland J T, Nolan J, Clarke B F, Oliver M F

出版信息

Diabetes. 1968 Jul;17(7):458-67. doi: 10.2337/diab.17.7.458.

DOI:10.2337/diab.17.7.458

PMID:4875170

Abstract

摘要

相似文献

A three-year trial of atromid therapy in exudative diabetic retinopathy.

Diabetes. 1968 Jul;17(7):458-67. doi: 10.2337/diab.17.7.458.

A controlled trial of Atromid therapy in exudative diabetic retinopathy.

Trans Ophthalmol Soc U K (1962). 1964;84:281-95.

Treatment of exudative diabetic retinopathy with atromid-S.

Ophthalmologica. 1968;156(1):2-5. doi: 10.1159/000305357.

[Action mechanism and clinical success of Regelan (Clofibrate)].

Wien Klin Wochenschr. 1967 Sep 29;79(39):716-20.

Observations on the effect of ethyl a-p chlorophenoxyisobutyrate (CPIB) therapy on serum lipid levels and on diabetic and some other retinopathies.

Acta Ophthalmol (Copenh). 1968;46(2):162-70. doi: 10.1111/j.1755-3768.1968.tb05172.x.

Clinical trial with ethyl-a-p-chlorophenoxyisobutyrate (Atromid-S) with special reference to white blood cell counts.

Acta Med Scand. 1966 Nov;180(5):519-31. doi: 10.1111/j.0954-6820.1966.tb02865.x.

[The treatment of exudative diabetic retinopathies with clofibrate (Atromid-S)].

Ned Tijdschr Geneeskd. 1967 Nov 11;111(45):2039-40.

Atromid-S for the reduction of plasma lipids.

Med Lett Drugs Ther. 1967 Jun 16;9(12):45-7.

Atromid and platelet adhesiveness in multiple sclerosis.

J Atheroscler Res. 1967 May-Jun;7(3):397-400. doi: 10.1016/s0368-1319(67)80069-3.

The treatment of diabetic retinopathy.

Geriatrics. 1968 Jul;23(7):137-48.

引用本文的文献

Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?

Curr Atheroscler Rep. 2025 Mar 20;27(1):39. doi: 10.1007/s11883-025-01292-0.

Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies.

Diabetologia. 2022 Apr;65(4):587-603. doi: 10.1007/s00125-022-05655-z. Epub 2022 Feb 11.

REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy.

J Lipid Atheroscler. 2020 Sep;9(3):406-418. doi: 10.12997/jla.2020.9.3.406. Epub 2020 Sep 18.

Reporting quality and adherence of randomized controlled trials about statins and/or fibrates for diabetic retinopathy to the CONSORT checklist.

Trials. 2019 Dec 16;20(1):729. doi: 10.1186/s13063-019-3868-4.

Statins and/or fibrates for diabetic retinopathy: a systematic review and meta-analysis.

Diabetol Metab Syndr. 2019 Nov 8;11:92. doi: 10.1186/s13098-019-0488-9. eCollection 2019.

The role of dyslipidemia in diabetic retinopathy.

Vision Res. 2017 Oct;139:228-236. doi: 10.1016/j.visres.2017.04.010. Epub 2017 May 26.

Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review.

JMIR Res Protoc. 2017 Feb 22;6(2):e30. doi: 10.2196/resprot.6650.

Role of lipid-lowering agents in the management of diabetic retinopathy.

World J Diabetes. 2017 Jan 15;8(1):1-6. doi: 10.4239/wjd.v8.i1.1.

Clofibrate in insulin-dependent diabetes.

Ir J Med Sci. 1979 Dec;148(1):31. doi: 10.1007/BF02938046.

Ocular complications of diabetes mellitus.

World J Diabetes. 2015 Feb 15;6(1):92-108. doi: 10.4239/wjd.v6.i1.92.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验